Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects

Why is Home Depot acquiring GMS for $5 billion? How will Netflix's NASA streaming deal impact viewership? What caused Apple to accuse an engineer of stealing secrets? Why is Trump pressuring the Fed to cut interest rates? How is Meta’s AI hiring spree affecting its stock? What are the effects of Canada scrapping its tech tax? Why did JetBlue cancel major winter flights from New York?

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects

benzinga.com/news/health-care/25/06/46175014/amgens-gastric-cancer-drug-improves-survival-in-phase-3-notes-ocular-side-effects

Amgen Inc (NASDAQ:AMGN) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6).
The study met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.
Bemarituzumab plus chemotherapy demonstrated a…

This story appeared on benzinga.com, 2025-06-30 16:53:02.